Navigation Links
Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time
Date:7/28/2011

Q2 2011 primarily due to the mix of customer sales affecting the rebate calculation. We expect ADDERALL XR's sales deductions to be closer to the 65-70% range for the remainder of the year.

ELAPRASE- Hunter syndrome

The growth in sales of ELAPRASE was driven by increased volumes across all regions in which ELAPRASE is sold and the timing of large orders from certain markets which order less frequently falling in Q2 2011 rather than Q1 2011. Reported ELAPRASE sales also benefited from favorable foreign exchange, due to the weaker US dollar in Q2 2011 compared to Q2 2010.

REPLAGAL - Fabry disease

The growth in REPLAGAL product sales was driven by the treatment of new patients, being both naïve patients and switches from the competing enzyme replacement therapy product. Reported REPLAGAL sales also benefited from favourable foreign exchange, due to the weaker US dollar in Q2 2011 compared to Q2 2010.

LIALDA/MEZAVANT - Ulcerative colitis

LIALDA/MEZAVANT product sales continued to grow in Q2 2011, driven primarily by increased US prescription demand due to higher US market share, the effect of price increases taken since Q2 2010 and stocking in Q2 2011 compared to destocking in Q2 2010.

VPRIV - Gaucher disease

VPRIV has seen significant growth since its approval in the US in Q1 2010 and in Europe in Q3 2010. Growth in patients being treated with VPRIV continues and we are progressing with our launch plans in countries across Europe. Reported VPRIV sales also benefited from favourable foreign exchange, due to the weaker US dollar in Q2 2011 compared to Q2 2010.

INTUNIV - ADHD

INTUNIV prescription demand continues to grow strongly, up 88% compared to Q2 2010. The growth in product sales was less than US prescription demand due to higher sales deductio
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. Neogen Reports 27% Increase in Quarterly Net Income
2. Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be
3. Microbix Has Best-Ever Quarterly Sales
4. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
5. China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010
6. Shires Replenished Portfolio Drives Excellent Quarterly Performance
7. Quest Diagnostics Declares Quarterly Cash Dividend
8. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
9. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
10. Abbott Declares 343rd Consecutive Quarterly Dividend
11. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... has sepsis, a life-threatening condition in which bacteria or ... fast for antibiotics to help. A new device inspired ... at Harvard,s Wyss Institute for Biologically Inspired Engineering may ... "Even with the best current treatments, sepsis patients are ... of the time," said Mike Super, Ph.D., Senior Staff ...
(Date:9/15/2014)... September 15, 2014 Bioptigen ... imaging OCT system for the optical device metrology and ... EnvisuTM S4410 SDOCT for Contact Lens Metrology is ... and high complexity contact lens, IOL structures, and donor ... a complete contact lens immersed in a hydration bath ...
(Date:9/15/2014)... Sept. 15, 2014 Research and Markets ... Market by Product, by Services, by Technology, by Application - ... Whole Exome Sequencing (WES) is next-generation technology used ... the exon. The exome, which is the total of all ... genome and is actually converted into proteins after translation. It ...
(Date:9/15/2014)... Die zweite jährliche International Plasma ... 18. Oktober stattfinden. Die IPAW ist eine gemeinsame ... (PPTA) und ihrer Mitgliedsunternehmen und hat ... für die Gewinnung von Quellplasma zu steigern ... Verbessern von Leben zu würdigen , Das ...
Breaking Biology Technology:Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3
... , , , FORT ... Board: OMCM), a leader in integrated electronic data capture (EDC) ... selected by a leading European based Contract Research Organization (CRO) ... in rheumatoid arthritis (RA). Phase III clinical studies serve to ...
... ANNAPOLIS, Md., Aug. 13 PharmAthene, Inc. (NYSE Amex: ... chemical threats, today reported financial and operational results for the second ... For the second quarter of 2009, PharmAthene recognized revenues ... of 2008. For the six months ended June 30, 2009 ...
... China, Aug. 13 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc., (NYSE ... of,modernized traditional Chinese medicine ("TCM") based in Chengdu, China, ... State Food and Drug,Administration (SFDA) to produce Sanqi Tablets ... and Yinqiao Jiedu Tablets in,dosage form of 0.5 gram/tablet ...
Cached Biology Technology:Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 3PharmAthene Reports Second Quarter 2009 Financial and Operational Results 4PharmAthene Reports Second Quarter 2009 Financial and Operational Results 5PharmAthene Reports Second Quarter 2009 Financial and Operational Results 6PharmAthene Reports Second Quarter 2009 Financial and Operational Results 7PharmAthene Reports Second Quarter 2009 Financial and Operational Results 8Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets 3
(Date:9/15/2014)... that reef biodiversity may not provide the level of ... In an international study published today, Professor David Bellwood ... Studies (Coral CoE) says we need to identify and ... In coral reefs, just as in any modern-day society, ... and functioning. , Professor Bellwood says, in many ...
(Date:9/15/2014)... million years after it formed may have been surprisingly ... and active crustal plates. , This alternate view of ... substantial new support from the first detailed comparison of ... ago with those formed contemporaneously in Iceland, which has ... Earth. , The study was conducted by a team ...
(Date:9/15/2014)... who transplanted combinations of wild, domesticated, and ... to new environments found that within 5 ... foreign genes from wild populations that hybridized ... Applications study provides evidence that natural ... that hybridized populations experience as a result ...
Breaking Biology News(10 mins):Specialized species critical for reefs 2Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... Australian scientists have found that the bacterium Cupriavidus ... toxic gold compounds to their metallic form using active ... on gold surfaces but have never clearly elucidated their ... that there may be a biological reason for the ...
... . , Leishmania is a deadly parasitic disease ... million new cases reported every year. Until recently, scientists were unsure ... now been solved according to a new study published in ... a scientist at the Research Institute of the McGill University ...
... Communication Intelligence Corporation ("CIC") (OTC Bulletin Board: ... for business process automation in the financial industry* ... announced today that a top-three U.S. bank will ... rollout including several thousand recently acquired branches. , ...
Cached Biology News:Bacterium helps formation of gold 2Major discovery opens door to leishmania treatment 2Top-Three US Bank Chooses CIC Electronic Signature Technology for Branch-Wide Deployment 2Top-Three US Bank Chooses CIC Electronic Signature Technology for Branch-Wide Deployment 3
...
CREB-2 (H-290)...
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Biology Products: